BrainMap

Ileana Manduteanu

phD in Biological Sciences

Researcher ,Deputy director - INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU''

Researcher | Scientific reviewer | Manager | PhD supervisor

Web of Science ResearcherID: AAX-8661-2020

Curriculum Vitae (02/02/2023)

Expertise & keywords

COST ACTION CA20117 “Converting molecular profiles of myeloid cells into biomarkers for inflammation and cancer”, Call name:
2021 - 2025

Role in this project: Partner team leader

Coordinating institution: University Hospital Essen, Germany

Project partners: University Hospital Essen, Germany ()

Affiliation: University Hospital Essen, Germany ()

Project website: http://www.cost.eu/actions/CA20117

Abstract:

Myeloid immune cells are important mediators in the pathology of many diseases, especially in diseases associated with chronic inflammation (DACI).

Recent advancements in molecular profiling technologies have led to the generation of large data sets, many of those not fully explored yet, but accessible

to the entire scientific community via public data repositories. It is the aim of this COST Action to repurpose those data sets, retrieve and curate myeloid

cell-specific information, and apply this information to develop novel biomarkers for DACI. To this end, Mye-InfoBank will utilise COST networking tools

to enable the interaction of molecular biologists, bioinformaticians, immunobiologists, biobank coordinators and clinicians.

The concerted activity of these experts on myeloid cell biology (either basic or clinical research) MYE, bioinformatics INFO,

and bio-banking BANK, will transform complex molecular information into standardised and applicable biomarkers, which have the potential to improve

clinical decision making in a number of socio-economically important diseases.

Impact of high glucose in valvular endothelial cells-monocyte crosstalk: molecular signatures and role in early valvular dysfunction Call name: P 1 - SP 1.1 - Proiecte de cercetare Postdoctorală - PD-2021
PN-III-P1-1.1-PD-2021-0498 2022 - 2024

Role in this project: Key expert

Coordinating institution: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU''

Project partners: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO)

Affiliation: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO)

Project website: http://www.icbp.ro/static/en/en-networking_grants-grants-national_grants/valdysign.html#:~:text=Rezultatele%20Etapei%20I%2C%20specifice%20activitatilor%20propuse%20in%202022%2C%20se%20poate%20gasi%20aici.

Abstract:

Aortic valve disease (AVD) and diabetes are progressive diseases that represent world-wide health problems. Diabetes is a risk factor for AVD, predicts faster disease progression and accelerates AVD. The mechanisms of early aortic valve dysfunction are still unclear, but evidence suggest that valvular endothelial cells (VEC) and monocytes (Mo) play key roles in the process. Our working hypothesis is that diabetic conditions (high glucose-HG) alters normal VEC-Mo interaction by progressively inducing molecular changes and function alteration in both cell types. The main goal of this project is to reveal the molecular signatures of VEC and Mo upon their interaction in HG conditions, to evaluate the role of key molecules in cell dysfunction and to propose novel mechanisms of early valvular dysfunction in diabetes. Our hypothesis will be tested by characterizing the molecular profile induced by HG in interacted VEC-Mo and by evaluating the function of relevant HG-induced molecules in endothelial permeability and monocyte adhesion/transmigration. HG-induced VEC and monocyte transcriptome will be analysed, and key molecules will be validated at gene and protein level. The role of relevant molecules will be investigated in endothelial permeability and monocyte adhesion/transmigration, early processes of valvular dysfunction in diabetes. Our project will provide important knowledge of early AVD in diabetes and might indicate new possible therapeutic targets for AVD in diabetes.

STROKE RISK PREDICTION IN ATHEROSCLEROSIS MEASURING CIRCULATING COMPLEMENT SYSTEM PROTEIN Call name: P 3 - SP 3.2 - Proiecte ERA.NET
ERANET-NEURON-STATEMENT 2020 - 2023

Role in this project: Partner team leader

Coordinating institution: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU''

Project partners: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO); Istituto di Ricerche Farmacologiche Mario Negri IRCCS (IT); IRCCS Ospedale Policlinico San Martino (IT); Institute of Clinical Medicine, University of Oslo (NO); Laboratoire CarMeN, Universite de Lyon (FR)

Affiliation: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO)

Project website: http://www.icbp.ro/static/en/en-networking_grants-grants-international/eranet_0463_statement.html

Abstract:

Stroke is the third cause of death and the first cause of long-term disability. Ischemic stroke accounts for 87% of all strokes. A major cause for ischemic stroke is represented by atherosclerotic vulnerable plaques, whose clinical detection is an unmet priority. The complement system is an inflammatory process involved in plaque’s morphological evolution. We aim at using the complement proteins as circulating bio sensors of plaque instability and stroke occurrence.

STATEMENT will focus on the pre-identified circulating complement biomarkers for plaque vulnerability, namely ficolins, initiators of the complement lectin pathway (LP). We will also analyze LP’s downstream active products and other complement pathway proteins seeking markers with enhanced sensitivity. We will retrospectively analyze available cohorts of atherosclerotic patients undergone endoarterectomy. The identified biomarkers will be analyzed in vitro to define their functional interactions with cellular plaque components, like macrophages, platelets, neutrophils and smooth muscle cells. The candidate biomarkers, selected on the basis of the retrospective patient study and on the in vitro study, will be finally tested in patients in a multicentric study (Italy, Norway and France).

STATEMENT will help advance prevention of neurologic complications and improve therapy by providing a marker for the early detection of rupture-prone atherosclerotic carotid plaques, bearing a risk for stroke.

Preclinical evaluation of newly designed vanadium compounds for diabetes therapy Call name: P 1 - SP 1.1 - Proiecte de cercetare Postdoctorală
PN-III-P1-1.1-PD-2019-0247 2020 - 2022

Role in this project: Key expert

Coordinating institution: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU''

Project partners: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO)

Affiliation: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO)

Project website: http://www.icbp.ro/static/en/en-networking_grants-grants-national_grants/diavan.html

Abstract:

Background and objectives. Type 2 diabetes mellitus (T2DM) is a metabolic disorder associated with hyperglycemia, resulting from impaired insulin secretion and increased insulin resistance (IR). Under IR, the liver unbalance between glucose and lipid metabolism leads to a reduced glucose uptake, determining the onset of hepatic steatosis. The aim of DIAVAN is to design and synthesize new vanadium-based compounds (VCs) to function as potent insulin-mimetic and anti-diabetic drugs. The DIAVAN objectives are: (1) Design, synthesis and characterization of new vanadium-based compounds with Schiff base derived from amino acids; (2) Evaluation of the potential of new vanadium-based compounds to reverse insulin-resistance induced in cultured human hepatocytes and (3) Study of the anti-diabetic effects of new vanadium-based compounds in a preclinical model of type 2 diabetes mice with insulin-resistance.

Experimental design. For objective 1, the new VCs will be synthetized by coordinating the Schiff base derived from amino acids and different aldehydes at vanadium ions. Physico-chemical characterizations and the ability of the new VCs to bind to serum proteins will be assessed by crystallographic and spectroscopic methods. For objective 2, in vitro IR reversing effect of the new VCs will be assessed in a human hepatocytes cell line, by quantification of molecules involved in insulin signaling, glycolysis and lipid metabolism, using immunological and colorimetric techniques. For objective 3, the in vivo anti-diabetic activity of the new VCs will be evaluated in the IR-T2DM C57BL/6J mice model by measuring the glucose, insulin and lipid levels in the blood and the lipid content in the liver, using immunological, colorimetric and optical imaging techniques. This innovative project combines the synthesis of the new VCs and the preclinical investigation of the VCs anti-diabetic potential, to develop a new therapeutic strategy for the treatment of T2DM.

Mimicking living matter mechanisms by five-dimensional chemistry approaches Call name: P 4 - Proiecte Complexe de Cercetare de Frontieră
PN-III-P4-ID-PCCF-2016-0050 2018 - 2022

Role in this project: Key expert

Coordinating institution: INSTITUTUL DE CHIMIE MACROMOLECULARA "PETRU PONI"

Project partners: INSTITUTUL DE CHIMIE MACROMOLECULARA "PETRU PONI" (RO); INSTITUTUL DE CHIMIE MACROMOLECULARA "PETRU PONI" (RO); INSTITUTUL DE CHIMIE MACROMOLECULARA "PETRU PONI" (RO); INSTITUTUL DE CHIMIE MACROMOLECULARA "PETRU PONI" (RO); INSTITUTUL DE CHIMIE MACROMOLECULARA "PETRU PONI" (RO); INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO); CENTRUL DE CHIMIE ORGANICA AL ACADEMIEI ROMANE "C.D.NENITESCU" (RO)

Affiliation: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO)

Project website: http://www.intelcentru.ro/5D-nanoP/

Abstract:

Mimicking the living matter mechanism of cooperation by complementarity represents one of the most challenging tasks of supramolecular chemistry. For now the solution consists in using particularly designed molecular unimers, endowed with the necessary amount of chemical information.

The 5D-nanoP project is dedicated to interfacing the fundamental research area of constitutional dynamic chemistry with the practical approaches of medicinal chemistry and biomedical applications. In the spirit of a metaphor of Jean-Marie Lehn (Nobel Prize in Chemistry, 1987), the project aims to materialize the concept of 5D chemistry in designing, synthesizing, characterizing, and using molecules with conditional affinity, to build versatile supramolecular nanoplatforms able to vectorize compounds of pharmaceutical or biochemical relevance, and genetic actuators, all of them involved in physiologic and pathologic processes at cell- and tissue-level.

The project will add the layer of 5D chemistry over the backgrounds of molecular assembling line techniques to produce particulate nanoplatforms, self-assemblable in the virtue of the chemical information stored by the designed unimer molecules. Two modern techniques of building dynamic chemical structures will be considered: (i) the use of self-immolative linkers, and (ii) the space stepwise and time phased (microfluidic) assisted synthesis. To prove the applicability of the produced nanoplatforms, an ex vivo cell cultivation system will be developed to emulate tissue/tumor niches.

Eight teams will be involved in the 5D-nanoP project to cover the main addressed research areas: (i) the in silico molecular design, (ii) the development of a unimers chemical library, (iii) the development of a molecular assembling line, (iv) the conjugation of the developed platforms with chemical species of biomedical interest, (v) the build of ex vivo emulating niches, and (vi) the bio-oriented assessment of nanoconstructs efficacy.

Intelligent therapies for non-communicable diseases based on controlled release of pharmacological compounds from encapsulated engineered cells and targeted bionanoparticles Call name: P 1 - SP 1.2 - Proiecte complexe realizate in consorții CDI
PN-III-P1-1.2-PCCDI-2017-0697 2018 - 2021

Role in this project:

Coordinating institution: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU''

Project partners: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO); UNIVERSITATEA POLITEHNICA DIN BUCURESTI (RO); INSTITUTUL NATIONAL DE CERCETARE - DEZVOLTARE PENTRU FIZICA MATERIALELOR BUCURESTI RA (RO); INSTITUTUL DE CHIMIE MACROMOLECULARA "PETRU PONI" (RO)

Affiliation: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO)

Project website: http://www.icbp.ro/static/en/en-networking_grants-grants-national_grants/intera.html

Abstract:

Non-communicable diseases (atherosclerosis, diabetes, obesity), a major cause of mortality, are characterized by associated inflammatory processes. The complex project INTERA aims to develop innovative therapeutic methods to ameliorate the pathological progression by reducing the inflammatory process. The multidisciplinary studies proposed by INTERA can create and define new nano- or micro-medical devices usable for smart and innovative anti-inflammatory therapies. INTERA includes 4 projects: (1) Encapsulation of genetically manipulated eukaryotic cells for controlled release of pharmacologically active products; (2) Development of a 3D platform designed for pre-clinical drug testing composed of cells incorporated into three-dimensional bio-matrices; (3) Intelligent nanobioparticles designed for bioactive compounds vectoring to pathological sites for vascular inflammation targeting. (4) Polymeric conjugates for efficiently inducing the expression of genes of interest with applicability in cellular therapy. The consortium consists of 4 partner research units - two institutes of the Romanian Academy (IBPCNS, ICMP), a university (UPB) and a national CD Institute (INCDFM) with good territorial coverage (Bucharest-Ilfov-Iasi). Predicted Indicators: 10 new R & D jobs, 8 ISI articles, 4 patent applications, 8 new technologies, 7 new service offers posted on the ERRIS platform. Institutional development: the new competences and the improvement of existing ones in partner units will attract the attention of the economic environment towards a better correlation of scientific and economic interests and better valorization in the field of drug science. From a social point of view, institutional development will lead to lowering the cost of these pathologies through new therapeutic approaches, more accessible to the population and hence, improving the quality of life.

Targeted therapies for aortic valve disease in diabetes Call name:
ID:P_37_298 2016 - 2020

Role in this project: Key expert

Coordinating institution: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU''

Project partners: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' ()

Affiliation: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' ()

Project website: http://theravaldis.icbp.ro/

Abstract:

THE EFFECT ON HUMAN HEALTH OF AG/TIO2NM-TREATED LEATHERS FOR FOOTWEAR INDUSTRY Call name: P 3 - SP 3.2 - Proiecte ERA.NET
ERA-SIINN-NanoSafeLeather 2015 - 2018

Role in this project:

Coordinating institution: INSTITUTUL NATIONAL DE CERCETARE-DEZVOLTARE PENTRU TEXTILE SI PIELARIE-I.N.C.D.T.P. BUCURESTI SUCURSALA BUCURESTI INSTITUTUL DE CERCETARE PIELARIE - INCALTAMINTE I.C.P.I.

Project partners: INSTITUTUL NATIONAL DE CERCETARE-DEZVOLTARE PENTRU TEXTILE SI PIELARIE-I.N.C.D.T.P. BUCURESTI SUCURSALA BUCURESTI INSTITUTUL DE CERCETARE PIELARIE - INCALTAMINTE I.C.P.I. (RO); INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO); TARO COMIMPEX S.R.L. (RO)

Affiliation: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO)

Project website: http://www.nanosafeleather.eu

Abstract:

Ecologic and health effects of applying materials with advanced functions for leather surface finishing are priorities for the European leather industry and contribute to the increase of added value and durability of leather and fur articles. The innovative properties of Ag/TiO2NMs on leather surface are due to their antimicrobial, self-cleaning and flame retardant characteristics. Furthermore, it leads to a reduction of chemicals with high pollutant potential. The cytotoxicity study of the Ag/TiO2NM’s efficiency for leather functionalization related to the dose response on human health is very important for their large scale application in footwear industry. In vitro assessment of the impact of Ag/TiO2NMs use in leather surface finishing on different human cell lines will enrich knowledge regarding MNMs effects on human health at cellular level. Computer simulation analysis, which tests hypotheses with in silico experiments, will provide new information on the morphology of human cell.

Molecules and mechanisms involved in cytokine and chemokine-dependent vascular inflammation as targets for novel nanotherapeutic strategies Call name: Exploratory Research Projects - PCE-2011 call
PN-II-ID-PCE-2011-3-0928 2011 - 2016

Role in this project: Project coordinator

Coordinating institution: Institutul de Biologie si Patologie Celulara "N. Simionescu"

Project partners: Institutul de Biologie si Patologie Celulara "N. Simionescu" (RO)

Affiliation: Institutul de Biologie si Patologie Celulara "N. Simionescu" (RO)

Project website: http://www.icbp.ro/static/en/en-networking_grants-grants-national_grants/refinater.html

Abstract:

Inflammation is a cause of many pathologies including atherosclerosis. Inflammatory mediators (cytokines and chemokines) affect resident vascular cells and infiltrated leukocytes function and their cross-talk with consequences for atheroma formation. We have found that resistin (R), a cytokine, and fractalkine (Fk) a chemokine, act as molecular links in vascular inflammation by a mechanism that is not known yet. Our goals are to search for the mechanisms by which Fk and R modulate the inflammation in endothelial cells (EC), smooth muscle cells (SMC), monocytes (M)/macrophages (Mac), if they contribute to SMC-Mac cross-talk, get insights in the signalling mechanisms and gene regulation involved, and develop new targeted nanotechnology-based therapeutic strategies o reduce vascular wall inflammation The objectives are 1. to explore the role of subendothelial resistin on M transmigration; 2. to analyze the R and Fk-induced M and SMC phenotype modulation and the molecular mechanisms involved in macrophage -SMC cross-talk and 3. to develop new targeted nanotherapeutic strategies to reduce vessels inflammation. Experiments will be done in cultured human EC, SMC and monocytes lines and validated on freshly isolated cells exposed to R and Fk in the presence/absence of chemical pharmacological modulators or gene specific siRNA directed to protein kinases and relevant transcription factors. The data will be applicable to the numerous diseases in which inflammation is involved.

Molecular inter-connection between chronic inflammation and atherosclerosis: the role of new discovered molecules, resistin, fractalkine and CXCL16; opportunities for new targeted therapies Call name:
Programul PARTENERIATE IN DOMENIILE PRIORITARE 2007-2013; Proie 2007 - 2010

Role in this project: Project coordinator

Coordinating institution: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU''

Project partners: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO); UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO); SPITALUL DE URGENTA AL MINISTERULUI ADMINISTRATIEI SI INTERNELOR "PROF.DR.DIMITRIE GEROTA" (RO)

Affiliation: INSTITUTUL DE BIOLOGIE SI PATOLOGIE CELULARA ,,NICOLAE SIMIONESCU'' (RO)

Project website: http://www.icbp.ro/labsites/crinchet/index.html

Abstract:

FILE DESCRIPTION	DOCUMENT
List of research grants as project coordinator
List of research grants as partner team leader
List of research grants as project coordinator or partner team leader
Significant R&D projects for enterprises, as project manager
R&D activities in enterprises
Peer-review activity for international programs/projects